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Abstract There are limitations on diagnostic methods to
differentiate between active and latent tuberculosis (TB), and
the prediction of latent progression to TB disease is yet
complex. Traditionally, tuberculosis-specific host immune
response was visualized using the tuberculin skin test.
Nowadays, IFN-γ release assays (IGRA) provide a more
specificandsensitivetool,bywhichexposuretoMtbcouldbe
determined. However, the merit of IGRA aids in diagnosing
active TB is yet unclear. We adapted IGRA for use in mice,
and quantifying bead-based flow cytometry techniques were
used to assess cytokine profiles during the course of untreated
infection and to investigate the value of IGRA and cytokines
as biomarkers for therapy response. High variability of IGRA
results during progression of active TB infection related to
various phases of infection was obtained. However, a
significant decrease in IGRA results and in levels of IFN-γ,
IL-17, IP-10 or MIG was observed and appeared to be
associated with successful therapy. This outcome does not
supportthevalueofIGRAtoaccuratelydiagnoseactiveTBor
to monitor infection progression. However, IGRA proved to
be a useful biomarker to monitor therapy success. In addition,
different cytokines might serve as biomarkers.
Introduction
Diagnosing tuberculosis (TB) remains complex and chal-
lenging. Differentiating between latent TB infections
(LTBI) and active TB is of vital importance. Various tools
for diagnosing TB are available. First, there is detection of
Mycobacterium tuberculosis (Mtb) in sputum and other
fluids (e.g. microscopic determination of bacilli, culture or
amplification of Mtb-specific genome parts). Second,
recognition of TB can be made in terms of disease
presentation (e.g. patient anamnesis or chest radiography)
or detection of a TB-specific host immune response (e.g.
tuberculin skin test (TST) or interferon gamma (IFN-γ)
release assays (IGRA). A limitation of the gold standard,
that is, Mtb culture, is that it may take as long as 6 weeks,
so more rapid detection of TB is needed. Therefore,
numerous studies have been performed to identify bio-
markers to detect TB infection, among which IGRA as
potential biomarker [1–4]. The dynamics of IGRA during
the course of untreated TB in not yet clear. The goal of the
present study was to provide further insight in this respect
and to investigate the value of IGRA as a biomarker to
monitor therapy response.
IGRA are in vitro tests detecting an immune response to
Mtb-specificantigens.IGRAwasintroducedinthelastdecade
as replacement of the TST and should provide more specific
test results in LTBI without cross-reactivity after a Bacillus
Calmette-Guérin vaccination [5]. Currently, two different
IGRA are available, QuantiFERON-TB Gold (QFT;
Cellestis Ltd, Carnegie, Victoria, Australia) and T.SPOT.
TB ELISpot (ELISpot; Oxford Immunotec, Abingdon,
UK). Both tests are based on quantitative measurement of
IFN-γ production by peripheral blood cells after stimula-
tion with the Mtb-specific peptides early-secreted antigen-
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10). Both IGRA showed excellent specificity that is
unaffected by earlier BCG vaccination [5]. Several studies
showed that T-SPOT.TB was more sensitive than QFT or
TST [2, 5]. An important annotation to these findings is
the absence of a gold standard to diagnose LTBI.
Nevertheless, the CDC recommended that QFT can be
used in all circumstances in which TST was used,
including contact investigations, evaluation of recent
immigrants, and sequential-testing surveillance programs
for infection control [6]. This advice is incorporated in
many national guidelines. At present the merit of IGRA
for diagnosing active TB, additionally to their use in
diagnosing LTBI, is still under debate.
From clinical studies the additional value of using
respiratory samples next to blood samples for IGRA is
not (yet) clear. It is hypothesized that an IGRA
performed in a sample from the primary site of infection
(e.g. the lungs) might differentiate between active TB
and LTBI. In patients bronchoalveolar lavage fluid or
pleural fluid is used in such a way [7]. In the present
study we also addressed this matter, by comparing
respiratory sample IGRA results with blood IGRA results.
Additionally, we assessed the cytokine/ chemokine profile
in serum samples from mice at the acute and chronic
phases of TB infection and during therapy and investigated
the diagnostic value of 17 immunological markers using a
multiplex panel of bead-labelled cytokine and chemokine
receptors.
In order to provide further insight into the dynamics of
IGRA we adapted IGRA for use in our murine TB model
[8]. A mouse model enables investigation of the value of
this new test during the acute phase and chronic phase of
infection and during standardized, well-controlled therapy.
In animal models comparative studies at similar conditions
of severity and duration of infection and therapy exposure
can be performed, which is difficult in patients due to
different underlying clinical conditions [9].
Materials and methods
Animals
Specified pathogen-free female BALB/c mice, obtained
from Charles River (Les Oncins, France) were infected at
10–12 weeks of age, as described previously [8]. The
experimental protocols adhered to the rules specified in the
Dutch Animal Experimentation Act and the published
Guidelines on the Protection of Experimental Animals by
the Council of the EC. The Institutional Animal Care and
Use Committee of the Erasmus MC Rotterdam approved
the present protocols.
Infection
Mice were infected through intratracheal instillation of a
40-μL suspension containing 9.4x10
4 CFU Mtb (H37Rv),
as previously described [8].
Anti-tuberculosis drugs
Therapy was administered from 4 weeks after the infection
onwards. The therapeutic regimen consisted of a combina-
tion of isoniazid, rifampicin and pyrazinamide during the
initial phase of 9 weeks, followed by a combination of
isoniazid and rifampicin during 4 weeks, as described
previously [8]. Anti-tuberculosis drugs were administered
in human pharmacokinetic-equivalent doses [10, 11].
Interferon-gamma release assay
Peptides ESAT-6 / CFP-10 were synthesized by Pepscan
(Pepscan Therapeutics, Lelystad, The Netherlands). Blood
samples were obtained from sacrificed mice by cardiac
puncture at indicated time points. In mice receiving therapy,
administration of anti-tuberculosis drugs was stopped 72 h
before dissection. Within 15 minutes of collection of blood,
the heparinized samples were diluted five times using a
mixture of RPMI 1640 medium (BioWhittaker–Cambrex,
East Rutherford, New Jersey, USA) enriched with 2 mM L-
glutamine (Invitrogen, Carlsbad, CA, USA), 100 units of
100 μg/ml penicillin-streptomycin solution (Invitrogen), 10%
heat-inactivated fetal calfserum (Invitrogen)and β-mercapto-
ethanol 0.002‰ (Sigma M7522, Sigma Chemical, St. Louis,
MO, USA). Samples were divided into three portions, and
stimulated with either concanavalin A (Invitrogen) in a final
concentration of 10 μg/ml (positive control) or with enriched
RPMI 1640 medium (negative control) or with a peptide
mixture of ESAT-6 and CFP-10 (Pepscan) both in a final
concentration of 0.25, 0.5, 1 or 2 μg/ml (Mtb-specific antigen
response). After incubation for 24, 48, 72 or 96 hrs, at 37°C
and 5% CO2,5 0μl of the supernatant was used to assess the
IFN-γ concentration in duplicate, employing the Mouse
IFN-γ ELISA-kit II according to the manufactures protocol
(Becton Dickinson, Franklin Lakes, NJ, USA) and a Bio-
Rad Elisa Reader model 680 (Bio-Rad Laboratories, Vee-
nendaal, the Netherlands). To prepare lung cell suspensions
from sacrificed mice the lungs were aseptically removed and
processed using a cell strainer with 70 μm nylon mesh
(Becton Dickinson). Cell suspensions were subsequently
processed according to the protocol described for blood.
Cytokine / chemokine concentrations in EDTA plasma
Quantification of cytokines / chemokines was performed
using a bead-based flow cytometry technique (xMap;
1196 Eur J Clin Microbiol Infect Dis (2012) 31:1195–1201Luminex Corporation, Austin, TX, USA). The mouse
soluble cytokine receptor multiplex panel used (Millipore
Corporation, Billerica, MA, USA), consisted of a bead-
labelled cytokine receptor against the following biomarkers:
GM-CSF, IFN-γ,I L - 1 β, IL-2, IL-4, IL-6, IL-10, IL-12
(p40), IL-13, IL-17, IP-10, M-CSF, MCP-1, MIG, MIP-1α,
MIP-1β and TNF-α. Tests were performed according to
manufactures protocol. Samples were tested in duplicates.
Results in median fluorescence intensity (MFI) values were
converted to pg/mL using MILLIPLEX Analyst software
(Millipore) and subsequently averaged. Statistical analysis
was performed using a two-tailed, unpaired Mann-Whitney
test. Only statistically significant (p-value ≤0.05) changes
in cytokine concentrations were presented.
Results
Adaptation and interpretation of IGRA in mice
with untreated TB infection
To optimize IGRA for use in our mouse TB model, in
blood samples obtained from phosphate buffered saline
(PBS)-inoculated control mice and TB-infected mice at
different ages, the optimum concentration of antigens
ESAT-6 and CFP-10 peptides and the optimum time period
of incubation were determined. In blood from TB-infected
mice a maximum IFN-γ production after stimulation with
1 μg/ml of each peptide was found and optimum time of
antigen exposure was 72 h (data not shown). IFN-γ
production level resulting from exposure of blood to Mtb-
specific-antigens minus IFN-γ concentrations present in the
negative controls was used as final read-out of the test and
referred to as IGRA results, similar to the evaluation of
IGRA results obtained in human blood.
At week four of the TB infection, six individual mice
were investigated; different responses were obtained
(Fig. 1). A distinct pattern per mouse was observed. Three
out of six mice showed that a high response in the positive
control (Fig. 1d) also showed a high response on Mtb-
specific antigens stimulation (Fig. 1b) and a high response
in the negative control (Fig. 1a). These mice still showed a
high IGRA result (Fig. 1c). Three out of six mice showed
overall lower responses.
IGRA in blood during the course of untreated TB infection
in mice
Dynamics in immune response, expressed in IGRA results
during the course of infection, are shown in Fig. 2. In the
acute phase of TB, the positive control response was
present at week 1 and remained at a certain level (Fig. 2b).
However, IGRA results were not observed at week 1, but
were significantly induced at week 3 and week 4 (Fig. 2a).
At the beginning of the chronic phase of the TB infection,
IGRA results dropped dramatically between week 4 and
week 9 (Fig. 2a), whereas positive control response did not
decrease (Fig. 2b). In order to determine sequestration,
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Fig. 1 IFN-γ production in
blood from six individual
mice at 4 weeks after untreated
TB infection. Blood samples
were processed in IGRA.
a Negative controls.
b Mtb-specific-antigens
responses after stimulation with
ESAT-6 and CFP-10.
c IGRA results (Mtb-specific-
antigens responses minus the
negative controls).
d Positive controls.
Data shown are mean IFN-γ
concentrations of measurements
in duplicate
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infected mice at 4, 9 and 17 weeks of infection. High IGRA
results in lung cell suspensions were observed at 4 weeks of
infection, reflecting high activity of lung T-cells upon
stimulation with Mtb-specific-antigens (data not shown).
During the course of infection IGRA results in lung cells
observed at week 4 decreased 15-fold at week 9 and
another 1.5-fold at week 17 (data not shown). From 9 weeks
after infection onwards IGRA results in blood gradually
and significantly increase until 15-fold response at week 17
compared to 9 weeks of infection (Fig. 2a). Interestingly,
also positive control response increased 4-fold in that
period (Fig. 2b).
IGRA in blood of TB-infected mice receiving therapy
IGRA results in blood from mice both after 5 weeks and
after 13 weeks of therapy were significantly decreased
compared to untreated TB-infected mice (Fig. 2a). Positive
control response did not significantly change after 5 weeks
of therapy, but was lower after 13 weeks of therapy
(Fig. 2b). When, after 13 weeks, the therapy was stopped,
IGRA results did not increase again at 6 weeks after
termination of therapy. Even at 13 weeks after therapy
termination, when relapse of TB infection in terms of
increased numbers of Mtb in the lung and histopathological
changes was observed [8], IGRA results remained low (data
not shown).
Cytokine or chemokine profile in plasma during the course
of untreated TB infection in mice and TB-infected mice
receiving therapy
Five of the 17 cytokines and chemokines assessed showed a
dynamic profile with significant changes during infection
progression or following therapy. IFN-γ concentration in
blood reached a maximum at 4 weeks after infection
(Fig. 3). During the chronic phase of infection IFN-γ
concentration significantly decreased. As found for IFN-γ
also IL-17 and IP-10 showed an initial increase, which
resulted in peak concentrations at 4 weeks after infection,
followed by a decrease from that time (Fig. 3). Dynamics of
TNF-α concentration showed a somewhat different pattern,
with increased concentrations from week 4 onwards. MIG
concentrations during the course of the untreated infection
were constant (Fig. 3).
In mice receiving therapy, concentrations of IFN-γ, IL-
17, IP-10 and MIG were decreased after 5 weeks of
therapy, which was also observed after 13 weeks of therapy
except for IFN-γ. Decreased levels of TNF-α were only
observed after 13 weeks of therapy (Fig. 3).
Discussion
In this study the dynamics of IGRA in TB infection and the
effect of therapy were investigated in a mouse model. To
this aim IGRA was optimized for use in mice. We observed
a variety in IGRA responses between individual mice,
which might be explained by differences in phase of TB
infection in these mice and hence the number of reactive
T-cells in blood. In a previous study, we showed that
around 4 weeks after Mtb inoculation, the acute phase of
infection progresses into the chronic phase [8]. At that time
point mouse to mouse variation in T-cell response can be
expected. Unfortunately, T-cell numbers in blood of TB-
infected mice could not be determined, since the
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Fig. 2 IFN-γ production in blood from mice (n=7) during the course
of untreated TB infection and TB-infected mice receiving therapy. Blood
sampleswere processed inIGRA.Mice withouttherapy(dark gray bars)
and mice receiving therapy (diagonally striped bars). a IGRA results
(Mtb-specific-antigens responses minus the negative controls). b
Positive controls. Data shown are mean IFN-γ concentrations of
measurements in duplicate. The whiskers represent the standard
deviation (SD). Statistical significance if present (p-value ≤0.05) is
indicated
1198 Eur J Clin Microbiol Infect Dis (2012) 31:1195–1201fluorescence-activated cell sorting technique using Mtb-
infected blood samples could not be performed at our
institute due to safety regulations.
Dynamics in immune response expressed in IGRA
results during TB showed a very slow start, which
might be due to T-regulatory cell activity in the initial
phase of infection, as described by Shafiani et al. [11].
However, a significant increase in IGRA results was
observed up to 4 weeks after infection. The observed fall
in IGRA results at 9 weeks after inoculation suggests that
this might be due to migration of specific T-cells to the
lung and/or due to strong regulation. IGRA results in lung
cell suspensions during the active phase of infection
showed indeed peak values at 4 weeks after infection.
These data are in concordance with the study of Arko-
Mensah et al. [1], showing that increased levels of (free)
IFN-γ in the respiratory tract correlated with active
pulmonary TB in mice. However, our observation that
IGRA results in lung T-cells decreased after 4 weeks of
infection (data not shown) discarded the hypothesis that
migration of T-cells to the lung was responsible for
decreased IGRA results in blood. Possibly the decline in
IGRA result might be due to down-regulation of T-cells
[12]. It may also be related to the IFN-γ depressing
capacity of Mtb during the active infection, by inhibiting
IFN-γ receptor signalling, as demonstrated in a study of
Sahiratmadja et al. [13]. The observed increase in IGRA
results and positive results from 9 weeks of infection
onwards might reflect an increase in cellularity associated
with severity of disease in mice during the advanced phase
of TB.
The data obtained in this animal model of TB do not
support the value of IGRA in blood to diagnose active
TB. IGRA responses are highly variable according to
various phases of active infection and might lead to
false negative results during active TB. These findings
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Fig. 3 Concentrations of
cytokines or chemokines in
plasma from mice (n=4) during
the course of untreated TB
infection and TB-infected mice
receiving therapy: mice without
therapy (dark gray bars)
and mice receiving therapy
(diagonally striped bars). Data
shown are mean concentrations
of cytokines or chemokines of
measurements in duplicate. The
whiskers represent the standard
deviation (SD). Statistically
significance if present
(p-value ≤0.05) is indicated
Eur J Clin Microbiol Infect Dis (2012) 31:1195–1201 1199are in line with a recent review by Hooper et al., who
concluded that there is inadequate evidence to support
the use of IGRA in the diagnosis or exclusion of active
pleural TB in patients [14].
However, the data of the present study suggest that
IGRA might be a useful biomarker to monitor therapy
response. Our results are in line with the findings obtained
by Lee et al., demonstrating that IGRA results decreased
after successful treatment [15]. In our experimental TB
model, it was also demonstrated that, next to IFN-γ, also
IL-17 and IP-10 as cytokines in the pro-inflammatory
reaction cascade, might be adequate markers indicative for
successful therapy. The results of the dynamics of free IFN-
γ concentrations as a biomarker during the different phases
of infection are in concordance with results earlier
described in other studies [8, 16]. However, it should be
noted that the free IFN-γ concentration level in blood is
also influenced by other factors not related to the TB
infection. The TNF-α concentrations also revealed a strong
increase during the acute phase of infection and sustained
high concentrations throughout the chronic phase of
infection. MIG concentrations showed no dynamics during
the course of infection but revealed to be an adequate
marker in therapy effect and in that perspective might
contribute to proper follow-up of patients starting anti-TB
therapy. These results indicate that besides IFN-γ also the
pro-inflammatory cytokines like IL-17, IP-10, TNF-α and
MIG are adequate biomarkers in the acute phase of
infection. Recruiting T-cells, macrophages and neutrophils
have a strong Th-1 reaction in this phase. In the present TB
model changes in cytokine concentrations can be related to
the TB infection. It should be realised that changes in pro-
inflammatory cytokines can be caused by many other
factors. However, the use of these cytokines to measure
therapy efficacy seems achievable when using two paired
samples taken before the start of therapy and after 3 weeks.
To our knowledge, only Beamer et al. reported
studies on the use of IGRA in a mouse TB model.
They showed that IGRA results from blood samples
after exposure to Mtb-specific-antigens reflected IGRA
results in lung cells [17]. They observed that a low IFN-γ
response to Mtb-specific-antigens was associated with
elevated risk of severe disease, compared to high
responders. Their study using various mouse strains
demonstrated that the course of TB was different and
dependent on the mouse strain used, which is also
reflected in their IGRA results [17].
Summarizing, the present study demonstrates a limited
value of IGRA to monitor infection progression or even to
detect active TB infection. These animal data do not
support use of IGRA as an accurate diagnostic tool for
active TB. By contrast, the value of IGRA in monitoring
therapy response in the acute phase of TB infection is
demonstrated. This may indicate that IGRA can be an
adequate biomarker for therapy failure due to Mtb resistance.
Also,adecreaseinplasmaconcentrationsofIFN-γ,IL -1 7,IP -
10 or MIG was associated with successful therapy. As it is
known that in TB patients the concentrations of cytokine
biomarkerscanbeinfluencedbyothernon-TB-relatedfactors,
IGRA as a TB-specific biomarker is preferable to be used for
monitoring therapy efficacy in TB patients.
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